Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Open Access
- 23 June 2022
- journal article
- review article
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 1 (1) , 57-65
Abstract
Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. NAFLD‐related cirrhosis is often complicated by portal hypertension (PHT). Recent evidence showed that portal venous pressure (PVP) starts to rise in the early stages of NAFLD, even in absence of advanced fibrosis or cirrhosis. However, the precise pathological mechanisms of this process are still poorly understood. Lipid accumulation, hepatocellular ballooning, sinusoidal endothelial cell dysfunction, capillarization, microthrombosis, increased angiogenesis, and pericellular fibrosis may all be involved in the early development of increased PVP in NAFLD. Direct measurement of PHT is invasive and impractical in noncirrhotic NAFLD individuals and may also underestimate its severity. Thus, the development and validation of noninvasive and more accurate measurements, including new serum biomarkers, scoring models, and imaging techniques (such as ultrasonography, elastography, and magnetic resonance imaging), are urgently needed. Owing to the increasing morbidity, challenges in the prevention and management of PHT in NAFLD are unprecedented. This review article aims to briefly discuss these challenges and summarizes the mechanisms, diagnosis, and emerging therapies for PHT in people with NAFLD.Keywords
Funding Information
- National Natural Science Foundation of China (82070588)
- Agenzia Italiana del Farmaco, Ministero della Salute (RF‐2016‐02364358)
This publication has 88 references indexed in Scilit:
- Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLDPLOS ONE, 2012
- Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 LociPLOS Genetics, 2011
- Increased production of sonic hedgehog by ballooned hepatocytesThe Journal of Pathology, 2011
- Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR LigandPLOS ONE, 2010
- Kupffer cells in non-alcoholic fatty liver disease: The emerging viewJournal of Hepatology, 2009
- Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitisHepatology, 2008
- Treatment of bile duct‐ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertensionLiver International, 2008
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the LiverPhysiological Reviews, 2008
- Effect of vardenafil, an inhibitor of phosphodiesterase‐5, on portal haemodynamics in normal and cirrhotic liver – results of a pilot studyAlimentary Pharmacology & Therapeutics, 2005
- Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2005